0.000159941839331167 0.000181752090149001 -0.000454380225372566 -0.000817884405670696 -0.000181752090149001 0.00109051254089426 0.000545256270447131 -0.00136314067611783
Sign Up Today X
Thanks for submitting the form.
Stockreport

Making U.S. biotech more competitive with China's could help rare disease patients, experts say [CNBC]

BioMarin Pharmaceutical Inc. (BMRN)  More Company Research Source: CNBC
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
China is pumping money into its biotech industry, helping launch a new wave of labs and incubators in the country. Experts say this could slow down American innovation in the biotech space. China's growth presents a conundrum for rare disease patients. The growth of China's biotechnology sector has been staggering. Beijing is pumping money into the industry, backing research efforts and helping launch a new wave of labs and incubators in the country. That's a problem for the U.S. biotech industry and also affects rare disease patients who are waiting for a cure. Among the experts speaking out against China's growing influence in the biotech sector is John Crowley, CEO of the lobbying group Biotechnology Innovation Organization, or BIO. Crowley is something of a rock star in the rare disease community. His story is as incredible as it is inspiring. When Crowley and his wife were told his two young children had Pompe disease, a fatal genetic disorder, Crowley left his job i [Read more]
IMPACT SNAPSHOT EVENT TIME: BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BMRN alerts
from News Quantified
BMRN
NEWS
BMRN
Earnings
BMRN
Analyst Actions
BMRN
SEC Filings
Stockreport

Making U.S. biotech more competitive with China's could help rare disease patients, experts say [CNBC]

BioMarin Pharmaceutical Inc.  (BMRN) 
More Company Research Source: CNBC
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
China is pumping money into its biotech industry, helping launch a new wave of labs and incubators in the country. Experts say this could slow down American innovation in the biotech space. China's growth presents a conundrum for rare disease patients. The growth of China's biotechnology sector has been staggering. Beijing is pumping money into the industry, backing research efforts and helping launch a new wave of labs and incubators in the country. That's a problem for the U.S. biotech industry and also affects rare disease patients who are waiting for a cure. Among the experts speaking out against China's growing influence in the biotech sector is John Crowley, CEO of the lobbying group Biotechnology Innovation Organization, or BIO. Crowley is something of a rock star in the rare disease community. His story is as incredible as it is inspiring. When Crowley and his wife were told his two young children had Pompe disease, a fatal genetic disorder, Crowley left his job i [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS